EarningsQ4 2025 Earnings Report
MX:SNYN Q4 2025 EPS Results
Actual EPS$16.70
Consensus EPS$15.40
Beat/MissBeat by +$1.30
One Year Ago EPS$12.50
MX:SNYN Q4 2025 Revenue Results
Actual Revenue$506.46B
Expected Revenue$248.18B
Beat/MissBeat by +$258.28B
YoY Revenue Growth+28.69%
Earnings Announcement Details
QuarterQ4 2025
Date01/29/2026
TimeBefore Open
Conference CallThursday, January 29, 2026
MX:SNYN Upcoming Earnings
Sanofi's next earnings date is estimated for October 30, 2026, based on past reporting schedules.
Q4 2025 Earnings Call Audio
MX:SNYN Q4 2025 Earnings Call
0:00 / 0:00
Q4 2025 Earnings Slide Deck
Q4 2025 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top-line growth (9.9% FY, 13.3% Q4), robust launch performance (EUR 5.7bn from new products), significant pipeline delivery and regulatory progress, improved margins and free cash flow, plus strategic BD/M&A activity. Notable challenges include a Phase III failure for tolebrutinib, a safety case in the amlitelimab program that will require monitoring, decreased Regeneron R&D reimbursements (offset partly by higher royalties), and some uncertainty in the U.S. vaccine schedule and vaccine sales in 2026. Overall, positives (growth, profitability, launches, pipeline replenishment and balance sheet flexibility) outweigh the lowlights, though execution and regulatory/safety risks remain important to monitor.Company Guidance
Strong Full-Year and Q4 Sales Growth
Net sales for full year 2025 were EUR 43.6 billion, a 9.9% increase at constant exchange rates. Q4 2025 sales were EUR 11.3 billion, up 13.3% year-over-year.
Robust Launch Performance and New Product Sales
New launches reached EUR 5.7 billion in sales and grew 34% in 2025. ALTUVIIIO reached blockbuster status with EUR 1.2 billion in full-year sales; AYVAKIT achieved $725 million annual pro forma sales; Beyfortus totaled EUR 1.8 billion (up 9.5%).
Dupixent Momentum
Dupixent posted EUR 4.2 billion in Q4 and EUR 15.7 billion in annual sales, with patient numbers increasing more than 30% over the past year; growth drivers include expansion into COPD, CSU and BP and a new regulatory acceptance for AFRS.
Vaccines Leadership and Impact
Vaccines sales were EUR 7.9 billion for 2025. Beyfortus has protected over 11 million babies across 45+ countries with real-world effectiveness of 87%–98%, estimated to have prevented ~200,000 hospitalizations to date.
Improved Profitability and Margins
Business gross margin expanded by 1.8 percentage points to 77.5%. Business operating income increased 11.9% with a BOI margin of 27.8%. Business EPS grew strongly (Q4 business EPS growth noted at 26.7%); full-year business EPS excluding buyback grew 12.2% and grew 15% including the completed EUR 5 billion buyback.
Strong Free Cash Flow and Balance Sheet
Free cash flow was EUR 8.1 billion (18.5% of sales) in 2025; inventory was reduced by nearly 30 days. Net debt was EUR 11 billion with a conservative 0.8x net debt-to-EBITDA ratio and maintained AA rating, enabling M&A and shareholder returns including a proposed EUR 1 billion buyback in 2026 and a 5% dividend increase to EUR 4.12.
Pipeline Delivery and Regulatory Progress
In 2025 the company delivered 12 Phase III readouts, 15 Phase II readouts, added 10 molecules to Phase I (including 3 gene therapies), obtained 20 regulatory approvals and 22 acceptances (including 9 priority reviews), and launched three new medicines/vaccines (Qfitlia, Wayrilz, Nuvaxovid).
Strategic BD & M&A Deployment
Opella divestment proceeds (~EUR 10.4 billion) were deployed into value-creating BD/M&A including Blueprint, Vicebio, Dren Bio DR-0201, Vigil and the proposed Dynavax acquisition (adds HEPLISAV-B and a shingles candidate).
Operational & Sustainability Initiatives
Continued investments in manufacturing capacity (strategic focus on U.S.) and participation in development of PAS 2090, the first industry-wide global standard for measuring and reducing environmental impact of medicines and vaccines.
2026 Financial Guidance
Guidance for full-year 2026: high single-digit sales growth and business EPS growing slightly faster than sales (profitable growth expected to continue over at least five years).
MX:SNYN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed